Elevar Therapeutics Reports Plans for Near-Term Resubmission of NDA for First-Line Treatment Option for Unresectable Hepatocellular Carcinoma Following Type A FDA Meeting
FDA confirmed resubmission can occur without delay FDA confirmed additional GMP and/or BIMO inspections may occur after resubmission Elevar plans to resubmit as soon as possible FORT LEE, NEW JERSEY, July 9, 2024 – Elevar Therapeutics, Inc. (Elevar), a majority-owned subsidiary of HLB Co.,
